Trafalgar International (GCAN) Liabilities and Shareholders Equity (2017 - 2026)
Greater Cannabis Company (GCAN) posted quarterly Liabilities and Shareholders Equity of $1439.0 for Q1 2026, down 96.89% year-over-year from $46213.0 in Q1 2025, and up 76.56% quarter-over-quarter from $815.0 in Q4 2025.
Trafalgar International (GCAN) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends
Greater Cannabis Company's Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $1439.0 for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 96.89% year-over-year to $1439.0; the TTM figure through Mar 2026 stood at $50321.0 (down 79.97% YoY), while the FY2025 annual figure was $815.0, down 98.59% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $1439.0, up from $815.0 in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $381756.0 in Q1 2022, with the low at $815.0 in Q4 2025.
- The 5-year median for Liabilities and Shareholders Equity is $133490.0 (2024), against an average of $153525.2.
- The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity advanced 2.45% in 2022, then tumbled 98.59% in 2025.
- Greater Cannabis Company's Liabilities and Shareholders Equity stood at $280447.0 in 2022, then sank by 38.57% to $172276.0 in 2023, then plunged by 66.46% to $57785.0 in 2024, then sank by 98.59% to $815.0 in 2025, then jumped by 76.56% to $1439.0 in 2026.
- Business Quant data shows GCAN's Liabilities and Shareholders Equity at $1439.0 in Q1 2026, $815.0 in Q4 2025, and $21355.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | 6.18 Bn |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | 1,439.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,439.00 |
| Dec 31, 2025 | 815.00 |
| Sep 30, 2025 | 21,355.00 |
| Jun 30, 2025 | 26,712.00 |
| Mar 31, 2025 | 46,213.00 |
| Dec 31, 2024 | 57,785.00 |
| Sep 30, 2024 | 63,949.00 |
| Jun 30, 2024 | 83,233.00 |
| Mar 31, 2024 | 133,490.00 |
| Dec 31, 2023 | 172,276.00 |
| Sep 30, 2023 | 206,199.00 |
| Jun 30, 2023 | 248,664.00 |
| Mar 31, 2023 | 260,720.00 |
| Dec 31, 2022 | 280,447.00 |
| Sep 30, 2022 | 300,761.00 |
| Jun 30, 2022 | 324,114.00 |
| Mar 31, 2022 | 381,756.00 |
| Dec 31, 2021 | 392,937.00 |
| Sep 30, 2021 | 509,775.00 |
| Jun 30, 2021 | 583,597.00 |